Addex Financial Statements From 2010 to 2024

ADXN Stock  CHF 0.06  0.0002  0.35%   
Addex Therapeutics financial statements provide useful quarterly and yearly information to potential Addex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Addex Therapeutics financial statements helps investors assess Addex Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Addex Therapeutics' valuation are summarized below:
Addex Therapeutics does not presently have any fundamental signals for analysis.
Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Addex Therapeutics Technical models . Check out the analysis of Addex Therapeutics Correlation against competitors.
For more information on how to buy Addex Stock please use our How to Invest in Addex Therapeutics guide.

Addex Therapeutics Company Shares Outstanding Analysis

Addex Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Addex Therapeutics Shares Outstanding

    
  115.35 M  
Most of Addex Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Addex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition
Based on the latest financial disclosure, Addex Therapeutics has 115.35 M of shares currently outstending. This is 36.11% lower than that of the sector and 7.95% higher than that of the Shares Outstanding industry. The shares outstanding for all Switzerland stocks is 79.83% higher than that of the company.

Addex Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Addex Therapeutics's current stock value. Our valuation model uses many indicators to compare Addex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Addex Therapeutics competition to find correlations between indicators driving Addex Therapeutics's intrinsic value. More Info.
Addex Therapeutics is rated third in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Addex Therapeutics' earnings, one of the primary drivers of an investment's value.

About Addex Therapeutics Financial Statements

Addex Therapeutics investors use historical fundamental indicators, such as Addex Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Addex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. ADDEX N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 17 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Addex Stock Analysis

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.